Brokerages expect Zoetis Inc (NYSE:ZTS) to post earnings per share of $0.67 for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Zoetis’ earnings. The highest EPS estimate is $0.71 and the lowest is $0.58. Zoetis posted earnings per share of $0.94 during the same quarter last year, which indicates a negative year-over-year growth rate of 28.7%. The company is scheduled to report its next earnings report before the market opens on Thursday, November 5th.
On average, analysts expect that Zoetis will report full-year earnings of $3.62 per share for the current financial year, with EPS estimates ranging from $3.52 to $3.66. For the next fiscal year, analysts anticipate that the business will report earnings of $4.11 per share, with EPS estimates ranging from $3.95 to $4.25. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Zoetis.
Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 6th. The company reported $0.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.25. Zoetis had a return on equity of 63.89% and a net margin of 25.50%. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.35 billion. During the same period in the previous year, the firm earned $0.90 earnings per share. The company’s revenue was up .1% on a year-over-year basis.
In other Zoetis news, EVP Heidi C. Chen sold 1,179 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $152.19, for a total value of $179,432.01. Following the sale, the executive vice president now owns 17,514 shares in the company, valued at $2,665,455.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Catherine A. Knupp sold 13,000 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $158.86, for a total value of $2,065,180.00. Following the completion of the sale, the executive vice president now owns 53,368 shares in the company, valued at approximately $8,478,040.48. The disclosure for this sale can be found here. Insiders sold 34,830 shares of company stock worth $5,524,068 in the last 90 days. Corporate insiders own 0.17% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in ZTS. Copper Rock Capital Partners LLC raised its stake in Zoetis by 6,026.7% in the second quarter. Copper Rock Capital Partners LLC now owns 8,331,273 shares of the company’s stock valued at $1,081,569,000 after buying an additional 8,195,290 shares during the period. Capital International Investors acquired a new position in shares of Zoetis in the first quarter valued at approximately $372,449,000. Capital Research Global Investors grew its position in shares of Zoetis by 66.2% in the first quarter. Capital Research Global Investors now owns 3,627,340 shares of the company’s stock valued at $426,902,000 after purchasing an additional 1,444,228 shares during the last quarter. FDx Advisors Inc. grew its position in shares of Zoetis by 419.0% in the first quarter. FDx Advisors Inc. now owns 1,192,944 shares of the company’s stock valued at $1,267,000 after purchasing an additional 963,076 shares during the last quarter. Finally, Nordea Investment Management AB grew its position in shares of Zoetis by 103.0% in the second quarter. Nordea Investment Management AB now owns 1,405,008 shares of the company’s stock valued at $188,032,000 after purchasing an additional 712,830 shares during the last quarter. Hedge funds and other institutional investors own 92.50% of the company’s stock.
Shares of ZTS stock traded down $1.77 on Friday, hitting $163.60. 25,808 shares of the stock were exchanged, compared to its average volume of 2,131,313. The company has a current ratio of 3.47, a quick ratio of 2.60 and a debt-to-equity ratio of 2.41. The firm has a market capitalization of $78.57 billion, a P/E ratio of 48.93, a price-to-earnings-growth ratio of 4.54 and a beta of 0.76. The business has a 50-day moving average of $159.31 and a 200 day moving average of $138.90. Zoetis has a fifty-two week low of $90.14 and a fifty-two week high of $166.79.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.